Stock Market Reviews

SLP (Simulations Plus, Inc.) News

Get the latest news, insights, and market updates on SLP (Simulations Plus, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• SLP Resources Berhad (KLSE:SLP) investors are sitting on a loss of 4.3% if they invested three years ago
  For many investors, the main point of stock picking is to generate higher returns than the overall market. But the risk...
  Dec 30, 2025 - $SLP
• Simulations Plus (SLP) Highlights FDA Alignment as Citizens Maintains Market Perform
  Simulations Plus, Inc. (NASDAQ:SLP) is one of the best healthcare AI stocks to buy now. On December 9, Simulations Plus, Inc. (NASDAQ:SLP) issued a press release highlighting how its technologies align with the FDA’s new regulatory direction. On December 2, the FDA released a draft guidance focused on streamlined nonclinical safety studies for monospecific monoclonal […]
  Dec 22, 2025 - $SLP
• Simulations Plus (SLP) Upgraded to Strong Buy: Here's What You Should Know
  Simulations Plus (SLP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  Dec 18, 2025 - $SLP
• Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development
  RESEARCH TRIANGLE PARK, N.C., December 18, 2025--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will host a virtual Investor Day on Wednesday, January 21, 2026.
  Dec 18, 2025 - $SLP
• Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date
  RESEARCH TRIANGLE PARK, N.C., December 17, 2025--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report first quarter fiscal 2026 financial results after the market close on Thursday, January 8, 2026.
  Dec 17, 2025 - $SLP
• When Should You Buy Simulations Plus, Inc. (NASDAQ:SLP)?
  While Simulations Plus, Inc. ( NASDAQ:SLP ) might not have the largest market cap around , it saw a significant share...
  Dec 15, 2025 - $SLP
• 3 Software Stocks to Watch as the Industry Gains Momentum
  Steady digital transformation and strong adoption of AI bode well for Computer Software industry participants like SNPS, DSGX and SLP amid broader market volatility.
  Dec 9, 2025 - $SLP
• Simulations Plus Positioned to Capitalize on FDA’s Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions
  RESEARCH TRIANGLE PARK, N.C., December 09, 2025--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today responded to the U.S. Food and Drug Administration’s draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies. The guidance encourages reduced reliance on animal studies and elevates mechanistic understanding, pharmacokineti
  Dec 9, 2025 - $SLP
• DSGX Q3 Earnings Top, Sales Up Y/Y Amid a Volatile Global Supply Chain
  Descartes Systems posts strong fiscal Q3 2026 gains with an EPS beat, rising revenues and the Finale deal expanding its cloud logistics reach.
  Dec 4, 2025 - $SLP
• Why Shares of Simulations Plus Soared This Week
  The stock has taken a beating over the past few years, so expectations may have been low.
  Dec 4, 2025 - $SLP